The value of the number-needed-to-treat method in antiepileptic drug trials

Epilepsia

Volumn 41, Issue 4, 2000, Pages 440-446

  Lesaffre, Emmanuel ^a   Boon, Paul ^b   Pledger, Gordon W ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Antiepileptic drug; Clinical trials; Number needed to treat; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE;

ARTICLE; CLINICAL STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; HUMAN; META ANALYSIS; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL ANALYSIS;

EID: 0034031658     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00186.x     Document Type: Article

References (17)

1. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996; 313:1169-74.
2. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
3. Elferink AJA, Van Zwieten-Boot BJ. Analysis based on number needed to treat shows differences between drugs studied. Br Med J 1997;314:603.
4. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
5. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
6. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995;310:452-4.
7. Lesaffre E, Pledger G. A note on the number needed to treat. Control Clin Trials 1999;20:439-47.
8. Hutton JL, Aitkin M. Number needed to treat: properties and problems. (submitted), 1999.
9. Altman DG. Confidence intervals for the number needed to treat. Br Med J 1998;317:1309-12.
10. Decks JJ, Altman DG, Dooley G, Sackett DLS. Choosing an appropriate dichotomous effect measure for meta-analysis: empirical evidence of the appropriateness of the odds ratio and relative risk [Abstract]. Control Clin Trials 1997;18:84S-5S.
11. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
12. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83.
13. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
14. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
15. Rosenfeld W, Abou-Khalil B, Morrell M, et al. Double-blind placebo controlled trial of topiramate adjunctive therapy for partial-onset epilepsy. [Abstract]. Epilepsia 1996;37(suppl 4):5.
16. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate for partial onset seizures in children. Neurology 1999;52:1338-47.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.